|
|||||
|
|
cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma |
|
| Authors: | Berberich Anne Schmitt Lara-Marie Pusch Stefan Hielscher Thomas Rübmann Petra Hucke Nanina Latzer Pauline Heßling Bernd Lemke Dieter Kessler Tobias Platten Michael Wick Wolfgang |
| Affiliation: | 1.Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany ;2.Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany ;3.Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany ;4.Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany ;5.Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany ;6.Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany ;7.Clinical Cooperation Unit, Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany ;8.Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ; |
| Abstract: | Journal of Neuro-Oncology - Anaplastic lymphoma kinase (ALK) is expressed in?~?60% of glioblastomas and conveys tumorigenic functions. Therefore, ALK inhibitory strategies with... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |